drugset / Trial / NCT05188209
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with EGFR-positive, HER2-negative, inoperable locally advanced or metastatic gastric cancer.
Timeline
- Start
- 2021-12-31
- Primary completion
- 2022-10-12
- Completion
- 2022-10-12
Outcome
Outcome not reported
Stopped (Business): “Study terminated due to sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Other / unclassified | 2 mg/kg | Intravenous |